Pirfenidone (PFD) is a new pyridone compound with a broad-spectrum anti-fibrosis effect, which can prevent and reverse the formation of fibrosis and scars; it was marketed by Shiono Yoshihide in 2008 and has been obtained. Approved by the U.S. Food and Drug Administration, it is the first drug that has proven to have a Chemicalbook effect on idiopathic pulmonary fibrosis (IPF) through a repeated, randomized, placebo-controlled Phase III clinical trial; and the drug is in the renal interstitium Fibrosis, liver fibrosis and other fibrotic diseases are also effective; at the same time, it is also effective in kidney disease (focal segmental glomerulosclerosis), hypertrophic cardiomyopathy, adult type I multiple neurofibroma, and adolescents. Type I multiple neurofibroma and plexiform neurofibroma, diabetes with kidney disease, phase II clinical studies of uterine leiomyoma have been widely used.
Complaint
